![IJMS | Free Full-Text | Valproic Acid as a Potential Inhibitor of Plasmodium falciparum Histone Deacetylase 1 (PfHDAC1): An in Silico Approach IJMS | Free Full-Text | Valproic Acid as a Potential Inhibitor of Plasmodium falciparum Histone Deacetylase 1 (PfHDAC1): An in Silico Approach](https://pub.mdpi-res.com/ijms/ijms-16-03915/article_deploy/html/images/ijms-16-03915-ag-550.jpg?1581000760)
IJMS | Free Full-Text | Valproic Acid as a Potential Inhibitor of Plasmodium falciparum Histone Deacetylase 1 (PfHDAC1): An in Silico Approach
![Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing | British Journal of Cancer Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-021-01570-z/MediaObjects/41416_2021_1570_Fig1_HTML.png)
Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing | British Journal of Cancer
![PDF) Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation PDF) Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation](https://www.researchgate.net/publication/282355635/figure/tbl1/AS:614147268042781@1523435527384/Patients-characteristics_Q320.jpg)
PDF) Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
![PDF) All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1 -mutated AML unfit for intensive chemotherapy and PDF) All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1 -mutated AML unfit for intensive chemotherapy and](https://i1.rgstatic.net/publication/309438313_All-trans_retinoic_acid_ATRA_in_non-promyelocytic_acute_myeloid_leukemia_AML_results_of_combination_of_ATRA_with_low-dose_Ara-C_in_three_elderly_patients_with_NPM1_-mutated_AML_unfit_for_intensive_che/links/583d1b8808ae1ff45983ece8/largepreview.png)
PDF) All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1 -mutated AML unfit for intensive chemotherapy and
![Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis - Journal of Geriatric Oncology Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis - Journal of Geriatric Oncology](https://www.geriatriconcology.net/cms/asset/d48a4009-2c38-489c-bb75-feca48461179/fx1.jpg)
Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis - Journal of Geriatric Oncology
![Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors | Chinese Medical Journal Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors | Chinese Medical Journal](https://mednexus.org/cms/asset/0d7a0fd8-2db1-4413-be19-08eea4e4d77e/cmj.2020.133.issue-06.cover.jpg)